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Abstract 
Background: ATP‑dependent chromatin remodelling complexes are responsible for establishing and maintaining 
the positions of nucleosomes. Chromatin remodellers are targeted to chromatin by transcription factors and non‑
coding RNA to remodel the chromatin into functional states. However, the influence of chromatin remodelling on 
shaping the functional epigenome is not well understood. Moreover, chromatin remodellers have not been exten‑
sively explored as a collective group across two‑dimensional and three‑dimensional epigenomic layers.
Results: Here, we have integrated the genome‑wide binding profiles of eight chromatin remodellers together with 
DNA methylation, nucleosome positioning, histone modification and Hi‑C chromosomal contacts to reveal that chro‑
matin remodellers can be stratified into two functional groups. Group 1 (BRG1, SNF2H, CHD3 and CHD4) has a clear 
preference for binding at ‘actively marked’ chromatin and Group 2 (BRM, INO80, SNF2L and CHD1) for ‘repressively 
marked’ chromatin. We find that histone modifications and chromatin architectural features, but not DNA methyla‑
tion, stratify the remodellers into these functional groups.
Conclusions: Our findings suggest that chromatin remodelling events are synchronous and that chromatin remod‑
ellers themselves should be considered simultaneously and not as individual entities in isolation or necessarily by 
structural similarity, as they are traditionally classified. Their coordinated function should be considered by preference 
for chromatin features in order to gain a more accurate and comprehensive picture of chromatin regulation.
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SWI/SNF, INO80, ISWI
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Background
Chromatin is a dynamic and multi-layered structure of 
which the core building block is the nucleosome. Nucle-
osomes are comprised of an octamer of histone proteins 
and 147 base pairs (bp) of DNA in approximately two hel-
ical turns [1]. The unique chromatin conformation of any 
given cell is typically maintained throughout divisions 
and serves as a physical barrier to transcription factors 
and other regulatory proteins in order to prevent pro-
miscuous gene expression [2, 3]. Thus, chromatin struc-
ture must be modulated for regulatory factors to access 
DNA when required. This is largely achieved through the 
movement of nucleosomes by ATP-dependent chromatin 
remodelling complexes, which utilise ATP hydrolysis to 
organise nucleosomes into an active (relaxed) or repres-
sive (compact) conformation. The process of chromatin 
remodelling provides means for regulating DNA struc-
ture with precision and accuracy to facilitate diverse cel-
lular processes including transcriptional regulation, DNA 
repair, DNA replication and cell cycle progression [2, 4]. 
However, despite growing research into the molecular 
and biochemical mechanisms of chromatin remodelling, 
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it is still not completely understood how remodelling 
complexes work together to position nucleosomes for the 
required chromatin function.
Beyond the physical nature of its structure, chromatin 
carries diverse gene regulatory information including 
post-translational modifications of histone proteins and 
DNA methylation [2, 4, 5]. These features, together with 
non-coding RNA (ncRNA) species, form the epigenome. 
Chromatin remodellers are drawn to their target regions 
by sequence-specific regulatory proteins or ncRNAs 
[6–8] and use their protein structural domains to iden-
tify epigenetic patterning and the ‘linker’ DNA between 
nucleosomes to identify their preferred nucleosome sub-
strate [3, 9–11]. Yet, it is important to consider that many 
regulatory regions of the genome are a composite of mul-
tiple epigenetic marks; therefore, there is a multifaceted 
relationship between chromatin remodellers and the 
epigenome. For example, bivalent promoters are charac-
terised by the trimethylation of histone 3 at both lysine 
4 (H3K4me3) and lysine 27 (H3K27me3) [12–14] and 
could therefore potentially be ‘read’ by remodellers rec-
ognising either of these marks. Additionally, these rela-
tionships are not linear as more than one remodeller may 
recognise a single histone modification [15]. Uncovering 
the extent of overlapping and unique activity of chroma-
tin remodeller proteins is of great interest and is essential 
for understanding the influence of the epigenetic signa-
ture on chromatin remodelling events at any given locus.
There are four structural families of chromatin remod-
ellers: switch/sucrose non-fermenting (SWI/SNF), 
imitation switch (ISWI), inositol requiring 80-like 
(INO80-like) and chromodomain helicase DNA binding 
(CHD) [3, 16–18]. Chromatin remodelling complexes 
share common features such as an essential catalytic 
ATPase and a high affinity for nucleosomes [2, 3, 16–18], 
yet the ATPases within these complexes have evolved 
unique features that pertain to their specific function. 
SWI/SNF ATPases contain bromodomains for recognis-
ing acetylated histones; ISWI ATPases contain a HAND/
SANT/SLIDE domain for recognising internucleosomal 
DNA, the INO80-like ATPases have a longer peptide 
chain between their two helicase domains that has been 
proposed to fit Holliday junctions and replication forks, 
and the CHD ATPases contain chromodomains [16, 
18–22] (Fig.  1a). It is known that remodellers can have 
both cooperative and opposing roles at the same genomic 
location in yeast and mice [23–27]; however, the extent 
of this has not been studied extensively in human cells. 
Importantly, there has been no study to date examin-
ing more than three remodellers concurrently in human 
cells, nor with simultaneous consideration of the epig-
enome, transcriptome and chromatin structural states. 
Moreover, the influence of the epigenome on remodeller 
function is not well understood.
Here, we have examined the binding profiles of eight 
different chromatin remodeller proteins and integrated 
these with extensive epigenomic data, including histone 
modifications, DNA methylation and chromosome archi-
tectural information. Our study reveals that chromatin 
remodellers can be stratified into two groups based on 
their binding enrichment at either ‘actively marked’ or 
‘repressively marked’ regions and their interactions with 
chromatin features of the epigenome.
Results
The degree of chromatin remodeller binding correlates 
with the remodeller gene expression levels in prostate 
cancer cells
To improve our understanding of the relationship 
between different chromatin remodellers, we sought to 
examine the genomic binding profiles of multiple chro-
matin remodeller proteins simultaneously from publicly 
available data obtained from LNCaP prostate cancer 
cells [28]. All eight remodellers examined are catalytic 
ATPases that form mutually exclusive complexes and 
together represent all four the structural families, unlike 
previous studies in mouse embryonic stem cells. The 
remodellers studied were BRG1 and BRM from the 
SWI/SNF family; SNF2H and SNF2L from the ISWI 
family; INO80 from the INO80-like family; and CHD1, 
CHD3 and CHD4 from the CHD family (Fig.  1a). We 
first assessed the gene expression level of each remodel-
ler using published RNA-seq data from LNCaP cells [29] 
and compared this to prostate tumour samples from The 
Cancer Genome Atlas (TCGA) database [30] to deter-
mine the validity of using LNCaP cells as a prostate can-
cer model to explore chromatin remodellers. We found 
a high concordance in the gene expression pattern for 
each remodeller between these data sets, where those 
genes displaying higher expression in clinical samples 
from TCGA (n = 486) also had higher expression in the 
LNCaP cell line (Additional file 1: Figure S1A–B). A simi-
lar comparison was made between a normal prostate 
epithelial cell line (PrEC) and the normal samples from 
TCGA (n = 52); the expression patterns of the remod-
ellers in PrEC cells mirrored that of the normal clinical 
samples (Additional file 1: Figure S1C–D). We calculated 
the Pearson correlation coefficient and found a strong 
positive linear relationship between the LNCaP cells and 
the TCGA tumours (Pearson R =0.8375552) and between 
the PrEC cells and the TCGA normal data sets (Pearson 
R =0.670013; Additional file  1: Figure S1E). The excep-
tion to this was SNF2L, which was significantly lower in 
LNCaP cells compared to the TCGA tumours.
Page 3 of 19Giles et al. Epigenetics & Chromatin           (2019) 12:12 
Using the ChIP-seq binding profiles of the eight chro-
matin remodellers from Ye et  al. [28], we next exam-
ined the number of individual binding sites for each 
remodeller and established they ranged from 712 for 
INO80 to 39,887 for SNF2H (Fig. 1b), and in total, there 
were 60,043 genomic regions bound by at least one 
a
BRG1
BRM
INO80
SNF2H
SNF2L
CHD1
CHD3
CHD4
S
W
I/S
N
F
IN
O
80
Li
ke
IS
W
I
C
H
D
HelicC
HelicC
HelicC
HelicC
HelicC
HelicC
HelicC
HelicC
DExx
DExx
DExx
DExx
DExx
DExx
DExx
DExx
Bromodomain
Bromodomain
HAND/SANT/SLIDE
HAND/SANT/SLIDE
Chromodomains
Chromodomains
Chromodomains
b
B
R
G
1
B
R
M
IN
O
80
S
N
F2
H
S
N
F2
L
C
H
D
3
C
H
D
4
C
H
D
1
0
2,500
5,000
45,000
N
um
be
r o
f B
in
di
ng
 S
ite
s
d
B
R
G
1
B
R
M
IN
O
80
S
N
F2
H
S
N
F2
L
C
H
D
3
C
H
D
4
C
H
D
1
0
25
50
75
100
Pe
rc
en
ta
ge
 o
f U
ni
qu
e 
si
te
s
c
DUSP22 IRF4
10kb
BRG1
BRM
INO80
SNF2H
SNF2L
CHD3
CHD4
CHD1
H3K4me3
H3K27ac
H3K27me3
H3K4me1
H3K9me3
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.0
2.0
0.0
2.0
0.0
2.0
0.0
1.0
0.0
1.0
DAB2IP
10kb
BRG1
BRM
INO80
SNF2H
SNF2L
CHD3
CHD4
CHD1
H3K4me3
H3K27ac
H3K27me3
H3K4me1
H3K9me3
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.0
2.0
0.0
2.0
0.0
2.0
0.0
1.0
0.0
1.0
BRG1
BRM
INO80
SNF2H
SNF2L
CHD3
CHD4
CHD1
H3K4me3
H3K27ac
H3K27me3
H3K4me1
H3K9me3
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.0
2.0
0.0
2.0
0.0
2.0
0.0
1.0
0.0
1.0
10kb
PPP4R2 EBLN2
Chr9: 124,355,000-124,000,000Chr3: 73,040,000-73,170,000Chr6: 350,000-400,000
Fig. 1 Chromatin remodeller occupancy and expression in LNCaP cells. a The domain organisation of each ATPase catalytic subunits of chromatin 
remodelling complexes used in this study. Each contains a SNF2‑like helicase comprising of DEXDc and HELICc domains, with each subfamily 
containing additional domains. Key domains defining each subfamily are shown. b Number of binding sites occupied by each remodeller from 
MACS2 peak calling. c Genome browser view of chromatin remodeller occupancy and key histone modification tracks in LNCaP cells with overlap 
of chromatin remodeller binding and where SNF2H is the only bound remodeller. d Percentage of remodeller protein‑binding sites unique to each 
remodeller (coloured) and percentage that overlaps with one or more of the other remodeller proteins (grey)
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chromatin remodeller. Upon visualising the remodeller 
binding sites, we observed several regions where mul-
tiple remodellers were bound, such as the intergenic 
region between DUSP22 and IRF4 on chromosome 6 
and upstream of the EBLN2 gene on chromosome 3 
(Fig.  1c). Additionally, there were several sites where 
a single remodeller was bound, such as CHD3 at the 
EBLN2 gene promoter and SNF2H within the DAB2IP 
gene (Fig. 1c). We observed that the majority of the bind-
ing sites occurred over regions marked by gene regula-
tory histone modifications. Over 75% of the remodeller 
binding sites were under 750  bp in size, corresponding 
to a span of ~ 1–5 nucleosomes (Additional file 1: Figure 
S2A–H), covering 0.93% of the genome. The degree of 
overlap between the remodellers varied extensively with 
the number of unique binding sites for each remodeller 
ranging from ~ 25 to ~ 50%, with the exception of SNF2H 
which had ~ 75% unique sites, likely paralleling the over-
all large number of binding sites for this remodeller 
(Fig. 1d).
Together, these data show that there is large variation 
in the number of genomic sites occupied by chromatin 
remodellers, with both independent and a high degree 
of overlapping activity between the remodeller proteins. 
Importantly, the high overlap in the number of binding 
sites containing at least two remodellers suggests there is 
widespread coordinated activity across the genome.
The epigenome stratifies chromatin remodellers into two 
groups: Group 1 is associated with ‘actively marked’ 
chromatin and Group 2 with ‘repressively marked’ 
chromatin
Chromatin remodellers do not exhibit sequence speci-
ficity in their binding and therefore have the potential 
to bind anywhere across the genome. However, as the 
majority of remodeller proteins contain domains tar-
geting nucleosomes with post-translational histone tail 
modifications [2, 31–33], it is expected that the bulk 
of binding will occur within histone ‘marked’ chro-
matin. We compiled histone modification ChIP-seq 
data sets from LNCaP cells [29, 34] and performed a 
chromatin multivariate hidden Markov model (chrom-
HMM) analysis to determine chromatin states based 
on the Epigenome Roadmap core model for chroma-
tin state discovery [35] (Additional file  1: Figure S3A-
B; see “Methods”). This analysis found that of the 
histone modifications examined, the ‘marked’ chroma-
tin (active, bivalent and repressive states) encompassed 
50.1% of the genome, while 49.9% is not marked with 
any of the histone modifications included in the analy-
sis (see “Methods”). Of the 60,043 remodeller binding 
sites, 64.18% fell within ‘actively marked’ chromatin 
(promoters, enhancers and transcriptionally active), 
16.26% fell within ‘repressively marked’ chromatin and 
1.80% within bivalent chromatin. Together, 82.24% of 
all remodeller binding occurred within ‘marked’ chro-
matin, confirming that remodellers are largely localised 
to regulatory regions of the genome and suggesting 
that the primary role of remodellers is to establish and 
maintain gene expression (Fig. 2a).
As our data show that the majority of chromatin 
remodeller binding occurs at histone ‘marked’ chromatin, 
we next examined the enrichment of remodeller binding 
across gene regulatory features. We specifically targeted 
‘actively marked’ and ‘repressively marked’ regulatory 
elements that are ‘marked’ with a composite of histone 
modifications. To define these regulatory chromatin fea-
tures, we used annotated transcription start sites (TSS) 
from GENCODE and classified the promoter as a 2  kb 
region surrounding the TSS. We then separated these 
promoters according to the histone modifications pre-
sent in LNCaP cells to classify them as active (H3K4me3 
and H3K27ac), facultative repressed (H3K27me3), con-
stitutively repressed (H3K9me3) and bivalent (H3K4me3 
and H3K27me3) (Fig. 2b). Additionally, we defined puta-
tive enhancers as being at least 2 kb away from an anno-
tated TSS and classified them as either active (H3K4me1, 
H3K27ac, p300 and DNaseI accessible; Additional file 1: 
Figure S3C) or poised (H3K4me1) (Fig. 2b), and analysed 
the chromatin remodellers at these regions.
(See figure on next page.)
Fig. 2 Chromatin remodellers bind to distinct regions of chromatin in two defined groups. a Percentage of all 60,043 remodeller binding sites in 
each chromHMM chromatin state compiled into active promoters (promoters and flanking promoters), transcription (strong and weak and at 5′/3′ 
ends of genes), active enhancers (genic and other enhancers), bivalent (enhancers, promoters, and flanking promoters), repressive (polycomb, 
weak polycomb, zinc finger repeats and heterochromatin), and unmarked (no core marks from the Roadmap Epigenome chromatin state model). 
b Schematic diagram of histone modifications present at ‘active’ and ‘repressive’ promoters and enhancers. ‘Active’ histone modifications are shown 
in green with increased spacing between nucleosomes, while ‘repressive’ histone modifications are shown in red with compacted nucleosomes. 
c–g, i Enrichment of chromatin remodeller binding sites at key gene regulatory features defined by ‘active’ and ‘repressive’ histone modifications. 
Significant enrichment is defined as a score above one and significantly depleted as below one with Benjamini–Hochberg adj p value, ***p < 0.001 
or **p < 0.05. h Genome browser view of chromatin remodeller occupancy and key histone modification tracks in LNCaP cells showing upstream of 
the SDC1 promoter and at the COPS4 promoter, which is occupied by all Group 1 remodellers and adjacent to exon 2 in COPS4 that is occupied by 
all Group 2 remodellers
Page 5 of 19Giles et al. Epigenetics & Chromatin           (2019) 12:12 
a
h
b
d
f
g
ie
B
R
G
1
SN
F2
H
C
H
D
3
C
H
D
4
B
R
M
IN
O
80
C
H
D
1
SN
F2
L
0
5
10
15
20
Ac
tiv
e 
Pr
om
ot
er
O
bs
er
ve
d 
/ E
xp
ec
te
d
B
R
G
1
SN
F2
H
C
H
D
3
C
H
D
4
B
R
M
IN
O
80
C
H
D
1
SN
F2
L
0
5
10
15
Ac
tiv
e 
En
ha
nc
er
O
bs
er
ve
d 
/ E
xp
ec
te
d
B
R
G
1
SN
F2
H
C
H
D
3
C
H
D
4
B
R
M
IN
O
80
C
H
D
1
SN
F2
L
0
2
4
6
Fa
cu
lta
tiv
e 
Re
pr
es
se
d
Pr
om
ot
er
 O
bs
er
ve
d 
/ E
xp
ec
te
d
B
R
G
1
SN
F2
H
C
H
D
3
C
H
D
4
B
R
M
IN
O
80
C
H
D
1
SN
F2
L
0
1
2
3
4
5
Co
ns
tit
ut
iv
el
y 
Re
pr
es
se
d
Pr
om
ot
er
 O
bs
er
ve
d 
/ E
xp
ec
te
d
B
R
G
1
SN
F2
H
C
H
D
3
C
H
D
4
B
R
M
IN
O
80
C
H
D
1
SN
F2
L
0
5
10
15
20
25
B
R
G
1
SN
F2
H
C
H
D
3
C
H
D
4
B
R
M
IN
O
80
C
H
D
1
SN
F2
L
0
c
29.67%
Promoter
(Active)
16.26%
Repressive
17.76%
Unmarked
1.80%
Bivalent
Percentage of Remodeller 
Binding Sites
12.62%
Transcription
(Active)
21.89%
Enhancer (Active)
***p<0.001
***
***
**p<0.05
nsns
***
***
***
***
***
**
***
**
ns ns ns
**
***
**
ns = not significant
Bi
va
le
nt
 P
ro
m
ot
er
O
bs
er
ve
d 
/ E
xp
ec
te
d
Po
is
ed
 E
nh
an
ce
r
O
bs
er
ve
d 
/ E
xp
ec
te
d
1
2
3
4
5
***
******
***
Active
H3K4me1
H3K27ac
H3K9me3
H3K4me3
H3K27ac
H3K27me3
Active
Constitutively
Repressed
Facultative
Repressed
Enhancers Promoters
Poised
H3K4me1
Bivalent
H3K4me3
H3K27me3
Group 2Group 1
Group 2Group 1
Group 2Group 1
Group 2Group 1
Group 2Group 1
Group 2Group 1
SDC1
2 kb
Chr2: 20,390,000-20,404,000
BRG1
BRM
INO80
SNF2H
SNF2L
CHD3
CHD4
CHD1
H3K4me3
H3K27ac
H3K27me3
H3K4me1
H3K9me3
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.0
2.0
0.0
2.0
0.0
2.0
0.0
1.0
0.0
1.0
G
roup 2
G
roup 1
BRG1
BRM
INO80
SNF2H
SNF2L
CHD3
CHD4
CHD1
H3K4me3
H3K27ac
H3K27me3
H3K4me1
H3K9me3
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.1
1.0
0.0
2.0
0.0
2.0
0.0
2.0
0.0
1.0
0.0
1.0
G
roup 2
G
roup 1
2 kb
COPS4
Chr4: 83,955,000-84,970,000
Page 6 of 19Giles et al. Epigenetics & Chromatin           (2019) 12:12 
We assessed whether each chromatin remodeller was 
bound at the gene regulatory features defined above, 
more (enriched) or less (depleted) than expected by 
chance using the Genome Association Tester (GAT) 
[36]. All chromatin remodeller proteins were signifi-
cantly enriched at ‘actively marked’ regulatory elements, 
(Fig. 2c–e; Additional file 1: Figure S4A). However, it was 
notable that they could be stratified into two distinct 
groups based on the level of enrichment at these regions. 
BRG1, SNF2H, CHD3 and CHD4, herein called Group 
1, were significantly more enriched compared to BRM, 
INO80, SNF2L and CHD1, herein called Group 2 (Stu-
dent’s unpaired T test, active promoters p = 0.04; active 
enhancers p = 0.0001; poised enhancers p = 0.0004). At 
gene regulatory regions marked by ‘repressively marked’ 
epigenetic features, the facultative and constitutively 
repressed promoters, the majority of Group 1 remodel-
lers were not significantly enriched, in contrast to Group 
2 (Fig. 2f, g). Concomitantly, there was a significant dif-
ference between the mean enrichment scores of Group 
1 and Group 2 remodellers at repressed regions (Stu-
dent’s unpaired T-test, facultative repressed promoters 
p = 0.016; constitutively repressed promoters p = 0.02). 
However, statistical enrichment at a particular genomic 
annotated feature does not determine the extent of 
direct overlap of remodeller binding sites at these fea-
tures. By examining the direct overlap within each group 
of remodellers, we found that there are common and 
unique binding sites (Additional file  1: Figure S4B-C); 
for Group 1 binding sites, only 22.6% contained two or 
more Group 1 remodellers (Additional file 1: Figure S4D), 
and for Group 2 binding sites, only 17.3% contained more 
than one Group 2 remodellers (Additional file  1: Figure 
S4E). Example regions bound by all Group 1 remodellers 
are illustrated upstream of the SDC1 promoter and at the 
COPS4 promoter, and adjacent to exon 2 of the COPS4 
gene for Group 2 (Fig. 2h). Therefore, while each group of 
remodellers was enriched at the same genomic features 
(i.e. binding occurs higher than expected by chance), 
there are only a small percentage of regions where all the 
remodellers bind together, highlighting varied roles for 
these remodellers.
We next examined bivalent chromatin, which exhib-
its both active and repressive epigenetic features. Given 
the above results, we hypothesised that both Group 1 
and Group 2 remodellers would be enriched equally at 
bivalent chromatin. We indeed found that all remodel-
lers were significantly enriched at bivalent promoters, 
and notably, we observed that Group 2 remodellers had 
significantly higher enrichment compared to Group 1 
(Fig. 2i; Student’s unpaired T-test, p =0.0004). This is in 
line with previous research showing low enrichment of 
BRG1 and CHD4 at bivalent chromatin [27].
We next performed the equivalent enrichment analysis 
using the chromHMM 15 state model (see “Methods”). 
Again, Group 1 remodellers had a mean enrichment 
score significantly higher than Group 2 at ‘actively 
marked’ regions and a lower score for ‘repressively 
marked’ regions (Additional file 1: Figure S5A-I), with the 
exception of intragenic enhancers. All remodellers were 
enriched across all three bivalent states in the model 
(bivalent promoter, flanking bivalent promoter and biva-
lent enhancer), but there was no significant difference 
between the Group 1 and Group 2 (Additional file  1: 
Figure S5  J-L; Student’s unpaired T-test, p =0.118). The 
chromHMM model also defines states of active transcrip-
tion, and we found that there is no significant enrichment 
of remodellers in the regions flanking active transcrip-
tion and all remodellers were significantly depleted from 
regions of active transcription (Additional file  1: Fig-
ure S5M–O). Moreover, as there is also no significant 
enrichment at intragenic enhancers (Additional file  1: 
Figure S5D), we speculated that sites of active transcrip-
tion (including the intragenic enhancers) may be due to 
the highly dynamic and transient nature of transcription, 
preventing a stable signal of the chromatin remodellers 
from being detected within these regions.
An interesting exception to the stratification of the 
remodellers described above is the presence of CHD1 at 
‘actively marked’ promoters. At both annotated ‘actively 
marked’ promoters (Fig. 2c) as well as promoters defined 
by the chromHMM segmentation (Additional file 1: Fig-
ure S5A), CHD1 is found to be significantly enriched at a 
level comparable to the Group 1 remodellers. As CHD1 
does not display the same level of significant enrichment 
at any other ‘actively marked’ regulatory regions, we 
speculate that non-epigenetic factors may be driving this 
high level of promoter binding.
We then took a second approach where we tested the 
average distribution of the ChIP-seq signal of key gene 
regulatory histone modifications: H3K4me3, H3K4me1, 
H3K27me3 and H3K9me3, across the remodeller bind-
ing sites (Additional file  1: Figure S6A–D). Our results 
demonstrated that the active histone marks, H3K4me3 
and H3K4me1, displayed a higher average signal across 
the binding sites of Group 1 remodellers, and repressive 
histone marks exhibited a higher average signal across 
Group 2 remodellers. This further confirms the asso-
ciation of Group 1 with ‘actively marked’ regions and 
Group 2 with ‘repressively marked’ regions. Additionally, 
at ‘actively marked’ promoters and bivalent promoters 
defined by these histone modifications, the Pearson cor-
relation coefficient between the remodellers in Group 1 
was higher compared to Group 2 (Additional file 1: Fig-
ure S6E–F), indicating that there is more similarity in the 
binding pattern between Group 1 compared to Group 2 
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at active regions. Furthermore, we found the converse 
was true for repressed promoters (Additional file 1: Fig-
ure S6G–H). Taken together, these data suggest that 
while all remodellers are associated with ‘actively marked’ 
chromatin states, Group 1 remodellers have a more pro-
nounced role at these ‘actively marked’ regions, while 
Group 2 remodellers play a greater role at ‘repressively 
marked’ regions.
Chromatin remodellers bind to AT‑rich DNA and are found 
at unmethylated regions
We were interested to know whether DNA methyla-
tion or the DNA sequence within the remodeller bind-
ing site could also stratify the chromatin remodellers 
into Group 1 and 2. Although chromatin remodellers are 
responsible for positioning nucleosomes, the genome-
wide patterning of nucleosomes is also determined in 
part by the DNA sequence, where there is a preference 
for DNA rich in ApT and TpA dinucleotides that are 
able to bend more sharply around the histone octamer 
[1, 37, 38]. We calculated the density of all four nucleo-
tides within each chromatin remodeller binding site and 
found a higher density of A and T nucleotides within the 
remodeller binding sites for all of the remodellers, and 
no difference between Group 1 and Group 2 (Additional 
file  1: Figure S7A-B). Additionally, the ApT and TpA 
dinucleotides within Group 1 and Group 2 remodeller 
binding sites occur as frequently as all other dinucleo-
tides in the genome, except for CpG dinucleotides (Addi-
tional file 1: Figure S7C–D). Together, this suggests that 
while intrinsic nucleosome positioning is determined 
in part by sequence composition, chromatin remodeller 
nucleosome targeting is not dependent on overall DNA 
sequence composition, nor does the sequence stratify 
remodellers into Group 1 and Group 2.
DNA methylation of cytosine residues occurs primarily 
in a CpG context and has a complex role. At promoters, 
it is associated with chromatin compaction, but in gene 
bodies it is associated with active expression [39–44]. 
We next examined whether DNA methylation was pre-
sent at the remodeller binding sites. Overall, we detected 
very low levels of DNA methylation across all remodel-
ler binding sites (Additional file 1: Figure S7E). However, 
we found that remodellers bound to regions with a higher 
CpG density had less DNA methylation within their 
binding sites and conversely regions with lower overall 
CpG density displayed higher the levels of DNA methyla-
tion (Additional file 1: Figure S7E–F).
CpG islands are defined as regions of DNA with 
high CpG density stretching beyond 500  bp [45]. A list 
of annotated CpG islands was obtained from UCSC, 
and promoter CpG islands defined as the intersection 
between CpG islands and Ensembl transcription start 
sites (see “Methods”). These were then divided into 
methylated (average methylation across the CpG island 
above 50%) or unmethylated using whole-genome bisul-
phite sequencing (WGBS) data generated from LNCaP 
cells [46]. There was a small, but significant difference 
in the CpG density of the methylated and unmethyl-
ated CpG islands (one-way ANOVA, p <0.001; Addi-
tional file 1: Figure S7G). By performing GAT statistical 
enrichment analysis, we found that methylated promoter 
CpG islands are depleted of all chromatin remodellers 
(Fig. 3a). This was due to only 12 total remodeller peaks 
(the sum of: one peak for BRG1, six peaks for CHD3 
and five peaks for SNF2H) overlapping methylated CpG 
islands. All eight remodellers displayed varying levels 
of positive enrichment at unmethylated promoter CpG 
islands (Fig. 3b), with the CHD family (both CHD3 and 
CHD4 from Group 1 and CHD1 from Group 2) show-
ing the highest level of enrichment. We next examined 
the ChIP-seq signal intensity of the remodellers across 
unmethylated promoter CpG islands, extending to ± 2 kb 
from the centre of the island. Interestingly, we noted that 
there was variation in the binding pattern of remodel-
lers. CHD1 and CHD3 bound closer to the centre of the 
island, BRG1, CHD4 and SNF2H bound at the borders 
and BRM, INO80 and SNF2L were depleted in the centre 
(Fig. 3c). This suggested that chromatin remodellers are 
associated with maintaining chromatin organisation at 
different parts of promoter CpG islands, and we propose 
that they work in coordination to maintain the accessibil-
ity status of the island; however, the remodellers do not 
stratify into Group 1 and Group 2 based on whether the 
island is methylated or unmethylated.
Chromatin preferentially occupied by Group 1 remodellers 
is nucleosome depleted
Nucleosome occupancy at regulatory features naturally 
represses transcription by creating an inhibitory struc-
ture, and therefore, regions of ‘actively marked’ chro-
matin are typically depleted of nucleosomes and have 
increased rates of nucleosome turnover and greater spac-
ing between nucleosomes. Since Group 1 remodellers 
are enriched at ‘actively marked’ chromatin regulatory 
regions, we next asked whether the genomic regions cor-
responding to Group 1 localisation are depleted of nucle-
osomes. First, we examined sites of nucleosome depletion 
from DNaseI hypersensitivity data from LNCaP cells [47]. 
Analysis of the correlation between chromatin remod-
eller presence and DNaseI sites revealed that Group 1 
remodeller occupancy is highly correlated with DNaseI 
hypersensitive sites (Fig. 4a), in addition to DNaseI sites 
being highly enriched for Group 1 remodellers (Fig. 4b). 
Given that DNaseI digestion does not detect all sites 
of ‘open’ chromatin [48], we assessed the link between 
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chromatin remodeller binding and accessible chromatin 
using an alternative method—nucleosome occupancy 
and methylation sequencing (NOMe-seq). NOMe-seq 
[48–50] uses exogenous methylation of GpC dinucleo-
tides to identify accessible chromatin regions devoid 
of nucleosomes or tight binding transcription factors. 
Importantly, this method also avoids cleavage bias found 
in DNaseI data [51]. We found that GpC methylation was 
higher at Group 1 remodeller binding sites compared to 
Group 2, suggesting that genomic regions occupied by 
Group 1 remodellers contain fewer nucleosomes than 
those regions occupied by Group 2 remodellers (Fig. 4c). 
These data are consistent with the preference of Group 
1 remodellers for ‘actively marked’ chromatin states and 
for Group 2 remodellers to localise to regions of more 
‘repressively marked’ chromatin.
Accessible chromatin is associated with active regula-
tory elements and gene activity. Therefore, to determine 
whether chromatin remodeller binding was correlated 
with gene expression in LNCaP cells, the ChIP-seq read 
counts of all Group 1 and Group 2 remodellers were 
pooled. Then, the difference between the read counts 
(signal) for Group 1 remodellers compared to Group 
2 remodellers at the promoters of expressed genes 
was calculated. Genes were separated into those with 
a higher level of Group 1 chromatin remodeller bind-
ing and those with a higher level of Group 2 remodeller 
binding at their promoters and the level of expression 
for each group plotted as transcripts per million reads 
(logTPM). Of the 22,393 genes that were actively 
expressed in LNCaP cells, 14,669 had a higher signal for 
Group 1 chromatin remodellers and 7724 had a higher 
signal for Group 2 chromatin remodellers at their pro-
moters. Genes with a higher level of Group 1 remodel-
lers had higher expression compared to those that had 
a higher expression of Group 2 remodellers (Fig.  4d), 
supporting the conclusion that Group 1 remodellers are 
associated with increased gene activity. We performed 
a gene ontology (GO) analysis of active genes that more 
highly bound by either Group 1 or Group 2 remodellers 
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using GREAT [52]. For gene promoters with higher 
Group 1 binding, the most significant GO terms 
enriched were related to the nucleosome, transcrip-
tional processes such as rRNA binding and tRNA mod-
ification, and mRNA processing (Fig. 4e). Enriched GO 
terms for active genes with a higher Group 2 remodel-
ler signal include those associated with mitochondrial 
processes such as ATP synthesis and respiratory chain 
activity (Fig.  4e). Together, this demonstrates that the 
Group 1 and Group 2 remodellers maintain and associ-
ate with the regulation of different cellular pathways.
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Group 1 and Group 2 remodellers are defined by chromatin 
architectural features
The above results determined the positioning of remod-
ellers at regulatory features in the context of histone 
post-translational modifications and DNA methylation 
in linear genomic space. However, chromatin is organ-
ised into a higher order by the formation of topologically 
associated domains (TADs) [53] that function to bring 
distal regulatory regions together for coordinated gene 
expression. Architectural proteins Lamin A/C, Lamin 
B and CCCTC-binding factor (CTCF) contribute to the 
formation of this three-dimensional chromatin structure. 
Lamin B and Lamin A/C configure the chromatin into 
Lamin-associated domains (LADs), with low accessibil-
ity [54]. LADs occur at the nuclear periphery, are heav-
ily marked with H3K9me3 and are typically associated 
with gene repression. Therefore, we hypothesised that 
Group 2 remodeller binding will co-localise with LADs. 
Instead, using ChIP-seq data of Lamin B and Lamin A/C 
binding sites [55], we found all of the chromatin remodel-
lers were significantly depleted (p < 0.001), suggesting that 
the tightly compacted chromatin at the nuclear periph-
ery does not require remodeller binding to maintain its 
repressive state (Fig. 5a, b). Similarly, CTCF has diverse 
roles in regulating chromatin and the epigenome, and 
it is well established that nucleosomes directly flank-
ing CTCF-binding sites are highly ordered, displaying 
a strong phasing pattern [48, 49, 56]. Previous research 
has shown that the ISWI remodeller protein SNF2H, 
but not the alternative ISWI ATPase SNF2L, contrib-
utes to this highly ordered array of nucleosomes around 
sites of CTCF occupancy when bound to chromatin 
[57]. Using CTCF ChIP-seq data, we found that similar 
to the ‘actively marked’ DNA regulatory elements, all 
remodelers were enriched at CTCF-binding sites, but 
Group 1 remodellers were more highly enriched com-
pared to Group 2 (Student’s unpaired T-test, p =0.018), 
with SNF2H displaying the highest level of enrichment 
(Fig. 5c).
We next examined the distribution of chromatin 
remodellers within the context of higher-order three-
dimensional chromatin structure itself using Hi-C data 
from LNCaP cells [29]. We divided chromatin into 
TADs (85.4% of the genome), TAD boundaries (2.6% of 
the genome) and unorganised chromatin (12.0% of the 
genome; Additional file 1: Figure S8A) and examined the 
distribution of Group 1 and Group 2 remodellers within 
each category. Remarkably, we found that 90% to 94% of 
Group 1 remodellers and 75% to 85% of Group 2 remod-
eller binding sites were located within TADs or at TAD 
boundaries, indicating that chromatin remodellers pref-
erentially localised to sites of highly organised chromatin 
(Fig.  5d). We performed the GAT analysis and found a 
small but positive and significant enrichment of all eight 
of the remodellers at both TADs and TAD boundaries 
(Additional file  1: Figure S8B–C), which was expected 
as the majority of the genome is within these organised 
chromatin structures.
Within TADs, chromatin forms DNA loops to facili-
tate interactions such as those between enhancers and 
promoters (Fig. 5e), and these loops are in part affected 
by the positioning of nucleosomes [58, 59]. Our previ-
ous work has shown cancer-specific anchor points of 
long-range chromatin ‘loops’ are enriched for enhancers 
and promoters and contain a remodelled epigenetic sig-
nature, where ‘active’ marks H3K4me1, H3K4me3 and 
H3K27ac are increased [29]. Whether chromatin remod-
ellers are enriched at the anchor points of these chro-
matin loops remains unknown. Our linear data suggest 
‘active’ chromatin ‘loops’ that bring together promot-
ers and enhancers would be more enriched for Group 1 
remodellers compared to Group 2. To test this, we sep-
arated the anchor points of the long-range chromatin 
loops into those that contained at least one active pro-
moter or active enhancer using the chromHMM chroma-
tin state data (Type A anchors, ~ 20% of all anchors) and 
a second group that did not contain either of these regu-
latory elements (Type B anchors, ~ 80% of all anchors). 
We found that at Type A loop anchors, the remodel-
lers continue to stratify into Group 1 and Group 2, with 
Group 1 chromatin remodellers significantly (p <0.001) 
more enriched than Group 2 (Fig.  5f, g). Interestingly, 
Type B loop anchors that were devoid of an active pro-
moter or enhancer were significantly depleted (p < 0.001) 
Fig. 5 Chromatin remodeller binding at chromatin architectural features. a–c Enrichment of chromatin remodeller binding sites at the binding 
sites of key chromatin architectural proteins as defined by their ChIP‑seq‑binding profiles. Significant enrichment is defined as a score above one 
and significantly depleted as below one with Benjamini–Hochberg adj p‑value, ***p < 0.001 or **p <0.05. d Percentage of remodeller binding sites 
in TADs, TAD boundaries and unorganised chromatin. e Schematic diagram depicting TADs in linear and 3D space with an inactive loop condensing 
chromatin and an active loop bringing an enhancer (orange oval) and promoter (blue flag) within close proximity. f–h Enrichment of chromatin 
remodeller binding at anchor points of chromatin loops defined by Hi‑C and histone modification data as containing an active promoter or 
enhancer or neither. Significant enrichment is defined as a score above one and significantly depleted as below one with Benjamini–Hochberg adj 
p‑value, ***p <0.001 or **p < 0.05. i The KLK region on chromosome 19 and a regions on chromosome 1 containing active loops (pink arcs) with 
Group 1 remodeller binding sites at the long‑range loop anchors shaded in grey, with complementary three‑dimensional view from Rondo (Rondo.
ws)
(See figure on next page.)
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of all chromatin remodellers (Fig.  5h), suggesting that 
these anchors do not require ongoing chromatin remod-
elling activity. Examples of chromatin loops with Group 
1 remodeller binding and active regulatory elements are 
found at the KLK locus on chromosome 19, and a gene 
dense region on chromosome 1 (Fig.  5i). Together, this 
demonstrates a role for all Group 1 remodellers in chro-
matin three-dimensional architecture.
Discussion
Chromatin stores important epigenetic information 
that is inherited across cell divisions. ‘Reader’ proteins, 
such as ATP-dependent chromatin remodelling com-
plexes, are required to interpret and modify chromatin 
when required. While several studies demonstrate that 
chromatin remodeller complexes have strong ties with 
regulatory chromatin [15, 23, 25, 27, 60, 61], little is 
known about how these complexes function as a group 
and interact with the different layers of the epigenome. 
We sought to address this interrelationship through the 
use of publically available data by examining the role of 
eight different chromatin remodeller proteins in LNCaP 
prostate cancer cells and integrating their binding pro-
files with multiple epigenomic data sets. This is the first 
extensive analysis of multiple chromatin remodellers 
together, with several layers of the epigenome at the 
same time in human cells. We found that there is sub-
stantial overlap in the binding sites of the remodellers at 
regulatory regions of the genome. Specifically, we found 
that the eight remodellers can be stratified into two dis-
tinct groups: Group 1 that was more highly enriched 
at ‘actively marked’ chromatin regions and Group 2 at 
‘repressively marked’ chromatin regions (Fig. 6).
Our data revealed that the grouping of chromatin 
remodellers is remarkably consistent across all of the 
‘actively marked’ and ‘repressively marked’ epigenetic 
features we examined but intriguingly, independent of 
the core modification of DNA methylation. Segrega-
tion into these two groups persists at both defined DNA 
regulatory elements and chromHMM chromatin states, 
which are a composite of histone modification marks. 
While Group 1 remodellers have a significantly higher 
enrichment than Group 2 at ‘actively marked’ regions, it 
is still noteworthy that all remodellers have some level 
of enrichment at these regions, which highlights the 
dynamic and complex nature of active chromatin. Previ-
ous research also demonstrates a role of Group 2 remod-
ellers at active chromatin in embryonic mouse cells such 
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as INO80 in maintaining open chromatin in pluripotency 
genes [62] and CHD1 and its role in RNA polII stalling 
in active gene expression [63]. We also note that we find 
some divergent results for the remodeler CHD1. A previ-
ous study in mouse embryonic stem cells found CHD1 to 
only be enriched at active promoters [27]. In our study, 
CHD1 had an equivalent level of enrichment at active 
promoters as the Group 1 remodellers, while still being 
enriched at ‘repressively marked’ chromatin together 
with the other Group 2 remodellers. These differences 
may be due to the different cell types, embryonic cells 
versus somatic cells, or may reflect differences between 
normal versus cancer cells. It will be interesting to inter-
rogate these differences in future studies.
It was surprising that upon investigation of the direct 
overlap within Group 1 and Group 2 remodeller bind-
ing sites, we found less than 6% were in common for 
the entire group. This suggests that, while remodel-
lers within the same group have high statistical enrich-
ment at the same class of regulatory elements, they do 
not always bind to the exact same genomic region. For 
example, Group 1 remodellers demonstrate a preference 
for ‘actively marked’ promoters as a collective group, but 
they often localise to their own subset of all active pro-
moters, showing that each remodeller potentially has a 
distinct and unique role. Additional data will be needed 
to further resolve the types of complexes each of the core 
remodeller proteins is capable of forming. Expansion of 
the existing ChIP-seq data to include various accessory 
subunits will help refine this analysis, in combination 
with fine-tuning existing definitions of DNA regulatory 
elements and chromHMM states. Broadly defined, the 
further subdivision of DNA regulatory elements and 
states will enable subtyping and will provide additional 
details to determine under which conditions, states and 
combinations these remodeller proteins act in a coordi-
nated or antagonistic manner.
For the purposes of this study, we did not include all 
known histone modifications in our analysis, including 
methylation of H4K20 and H4K16ac [64–66]. Thus, the 
proportion of remodeller binding found at ‘unmarked’ 
regions may contain histone modifications not present in 
our analysis. However, the key marks for defining DNA 
regulatory elements and genes were included and there-
fore provide a comprehensive view of key gene regula-
tory chromatin features, and moreover, less than 20% of 
binding sites fell within the ‘unmarked’ regions. As more 
histone modification data become available, such as his-
tone variants and histone modifications with a structural 
role, it will be interesting to determine whether these also 
stratify the remodellers in a similar fashion.
Interestingly, we found that remodellers consistently 
segregated into Group 1 and Group 2 at architectural 
chromatin features, such as chromatin loop anchors and 
CTCF sites, highlighting that chromatin remodellers are 
also associated with higher-order chromatin architecture. 
Previous to this study, BRG1 was the sole remodeller that 
had a demonstrated role in chromatin architecture and 
a well-established role in maintaining enhancer–pro-
moter interactions [11, 60, 67]. Additionally, in MCF10A 
cells, BRG1 increases the stability of TAD boundaries 
to strengthen enhancer–promoter chromatin loops and 
maintain the established patterns of gene expression. 
Subsequent loss of BRG1 binding weakens these inter-
actions, concomitant with a down-regulation of gene 
expression [68]. Our results infer that in fact, all Group 
1 remodellers—BRG1, SNF2H, CHD3 and CHD4—could 
have individual or a combinatorial role at chromatin loop 
anchors that contain active promoters or enhancers. 
When we examined the remodellers at LADs, however, 
we found them to be depleted of all remodellers. We also 
investigated the association with the architectural pro-
tein CTCF and found that Group 1 remodellers are more 
enriched at CTCF-binding sites compared to Group 2. 
Together, our data suggest Group 1 remodellers have a 
prominent role at ‘active’ chromatin loops, whereas ‘inac-
tive’ chromatin loops do not require remodeller binding 
to maintain their repressed state.
Our finding that the distribution of chromatin remod-
ellers across CpG islands follows three distinct patterns 
(BRG1, SNF2H and CHD4 at borders; CHD3 and CHD1 
in the centre and SNF2L, INO80 and BRM deplete from 
the centre of the island) suggests that there are differ-
ent mechanisms at play for maintaining nucleosome 
positions at these regions. It was surprising that neither 
CHD3 nor CHD4 showed any level of enrichment at 
methylated CpG islands. These remodellers form a key 
part of the NuRD complex that also contains MBD2, 
which prefers hypermethylated promoters [42]. It is pos-
sible that once the DNA of any given genomic region 
becomes methylated and the chromatin is compacted, it 
may no longer require the remodelling complex to stay 
bound to the chromatin.
Previous studies that have examined two to three 
remodeller proteins show consistency with our findings. 
The overlap of BRG1 and CHD4 has previously been 
reported in various cell types, where they were reported 
to have opposing control over regulatory chromatin 
[23, 26, 69, 70]. For example in mice, BRG1, CHD4 and 
SNF2H have extensive overlap in their binding patterns 
and it has been implied that the sequential order of their 
binding is important for their correct function [23]. In 
our data, we found that these remodeller proteins were 
also enriched at the same genomic features, suggesting 
they may also have opposing functions in LNCaP cells. 
Additionally, we found overlapping enrichment patterns 
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for CHD1 and ISWI remodeller SNF2L, which in yeast 
have been reported to have both competing and coordi-
nated functions. CHD1 and SNF2L are responsible for 
maintaining the phasing of nucleosomes at promoters, 
but compete for different nucleosome spatial arrange-
ments, impacting the kinetics of gene activation [15, 24, 
25, 71]. CHD1 and SNF2L also work together at gene 
bodies where they are thought to maintain chromatin 
integrity during transcription elongation by preventing 
histone exchange during nucleosome turnover [72–74]. 
Moreover, there has been report of overlapping activity 
between the ATPase subunits of the NuRD remodelling 
complex, CHD3 and CHD4 [20], which also occurred in 
our data.
Functional studies in human cancers have demon-
strated the integrated relationships of chromatin remod-
ellers, through the identification of synthetic–lethal 
relationships. Synthetic–lethal relationships occur where 
the cancer develops a loss of function for one protein 
that creates a dependency on another protein. Synthetic–
lethal relationships exist for ATPases, BRG1 and BRM, in 
triple negative breast cancer, for accessory subunits of the 
SWI/SNF complex, ARID1A and ARID1B, in colorectal 
cancer and CHD1 with transcriptional regulator PTEN 
in prostate cancer [75–77]. These instances of the rela-
tionship between remodellers and their function high-
light the importance of studying multiple remodellers 
together to provide a greater understanding of the overall 
mechanism of chromatin remodelling and how a chro-
matin state is established. It is unclear from our data how 
much of the remodeller binding overlap provides coop-
erative or antagonist function; moreover, our study does 
not determine the extent of competition between the 
remodellers for nucleosome binding. Mechanistic studies 
are now required, such as using gene editing approaches 
and in different cell model systems, to further dissect the 
importance and or redundancy of individual remodellers 
and their potential functional role in regulating chroma-
tin, and broaden the applicability of findings to other cell 
types.
Conclusions
In summary, our results reveal previously unknown rela-
tionships between the remodellers, and with both the 
two-dimensional and three-dimensional epigenome. We 
propose that chromatin remodellers should be examined 
in the context of the different classes of remodellers we 
identified as Group 1 or Group 2, and not solely with 
consideration to existing structural families or in isola-
tion (Fig.  6). These observations may inform decisions 
for future work that studies chromatin remodeller func-
tion and provides a more complete picture of chromatin 
remodelling action.
Methods
ChIP‑seq assay and data
LNCaP chromatin remodeller ChIP-seq data are from 
Ye et  al. [28]: GEO accession GSE72690. Histone modi-
fication LNCaP ChIP-seq data (H3K4me3, H3K4me1, 
H3K27ac and H3K27me3) are from Taberlay et  al. [29]: 
GEO accession GSE73785, and Bert et al. [34]: GSE38685. 
CTCF ChIP-seq data is from Bert et al. [34]: GSE38685. 
H3K9me3, H3K36me3, Lamin B and Lamin A/C ChIP-
seq data are from Du et al. [55], GSE98732. p300 ChIP-
seq data  is from Wang et  al. [78]: GSE27824. RNA 
polII ChIP-seq data  is from Tan et  al. [79]: GSE28264. 
All ChIP-seq data sets were processed as previously 
described in Bert et al. [34], Taberlay et al. [29], Du et al. 
[55] and Lund et al. [80]. Histone modification and chro-
matin remodeller peaks were called using MACS2 [81] 
and Lamin domains called with the enriched domain 
detector (EDD) [80]. Two ChIP-seq input data sets were 
provided by Ye et al. [28], which were merged for calling 
remodeller peaks. Then, MACS2 [81] was used to call 
peaks on each individual input data set; any peaks over-
lapping with the chromatin remodellers were removed 
from the remodeller data sets.
Hi‑C data
LNCaP Hi-C data is from Taberlay et al. [29]; GSE73785. 
Hi-C data were processed through the NGSANE frame-
work v0.5.2 [82] as previously described in Taberlay et al. 
[29]. TADs were identified with the ‘domain-caller’ pipe-
line [53] as described in Taberlay et  al. [29]. TADs and 
TAD boundaries were assessed at 40 kb resolution. The 
percentage of the genome covered by TADs and TAD 
boundaries was calculated by accumulating the num-
ber of base pairs within TADs or boundaries, divided by 
3.095 × 106 and then multiplied by 100. Chromatin loops 
were called from contact count matrices for 10 kb reso-
lution using a custom adaptation of Fit-Hi-C (contained 
in NGSANE; Buske et al. [82]) supplying iteratively cor-
rected bias offsets calculated through HiCorrector v1.1 
[83]. Chromatin loops were visualised in the WashU Epi-
genomics Browser [84] and Rondo (rondo.ws).
RNA‑seq data
LNCaP RNA-seq data are from Taberlay et  al. [29]: 
GSE73785, and processed clinical prostate tumour RNA-
seq was downloaded from TCGA (cancergenome.nih.
gov). LNCaP RNA-seq data (n = 3) were processed as 
described in Taberlay et  al. [29]. To determine chroma-
tin remodeller gene expression, reads mapped to hg19/
GRCh37 where counted into genes using featureCounts 
[85] program and GENCODE v19 used as a reference 
transcriptome to determine the transcript per million 
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read (TPM) value and biological triplicates were aver-
aged. Processed RNA-seq data (n = 486 tumours) from 
the TCGA prostate adenocarcinoma cohort were aver-
aged to determine chromatin remodeller expression in 
clinical prostate cancer samples. The log mean values 
for each remodeller were plotted as cancer versus nor-
mal between the cell lines (logTPM) and the normal and 
tumour TCGA data sets (logRKPM), along with the lin-
ear regression line of best fit. Pearson’s correlation coef-
ficients were calculated in R.
Chromatin accessibility data
DNaseI data  is from Thurman et al. [47], and processed 
data were downloaded from the ENCODE data portal 
(encodeproject.org/). DNaseI sites of accessibility from 
two biological replicates overlapped and the intersection 
from both replicates were used for downstream analysis 
(see Remodeller enrichment analysis). NOMe-seq data 
are from Valdes-Mora et al. [86]: GSE76334. NOMe-seq 
data were processed as previously described in Valdes-
Mora et  al. [86]. NOMe GpC methylation levels within 
remodeller binding sites were defined by first computing 
the methylation ratio of all GCH sites with greater than 
5× coverage and then calculating the mean methylation 
score within each remodeller binding site. Methylation 
density of remodeller binding sites was plotted in R. Vis-
ualisation of nucleosome occupancy at remodeller bind-
ing sites was created using ‘methylationPlotRegions’ from 
the aaRon package in R, ± 3000 bp from the centre of the 
remodeller binding site.
DNA methylation data
WGBS sequencing data is from Pidsley et  al. [46]: 
GSE86833. WGBS libraries were processed as previ-
ously described Pidsley et  al. [46]. CpG islands and 
Ensembl gene coordinates were downloaded from the 
UCSC genome browser [87]. Promoter CpG islands 
were defined as the intersection between CpG islands 
and the 5′ ends of Ensembl genes. The promoter CpG 
islands were split into 40 equally sized bins and the aver-
age methylation score calculated from the WGBS data 
using ‘ScoreMatrixList’ from the genomation package 
in R. Methylated CpG islands were defined as having an 
average methylation score above 50%. DNA methyla-
tion levels within remodeller binding sites were defined 
by first computing the methylation ratio of all cytosines 
with greater than 5× coverage and then calculating the 
mean methylation score within each remodeller binding 
site. CpG density of methylated and unmethylated CpG 
islands was calculated in R. Violin and boxplots plots 
were created in ggplot2 in R. Remodeller binding sites 
were overlapped with the methylated and unmethylated 
islands using the GRanges package in R.
ChromHMM segmentation based on Roadmap 
epigenomics
The Roadmap Epigenomics chromHMM model was 
based on five core histone modifications (H3K4me3, 
H3K4me1, H3K36me3, H3K27me3, H3K9me3) and 
trained on 60 epigenomes [88] to categorise the genome 
into 15 chromatin states. There were seven chroma-
tin states associated with ‘active’ chromatin; active pro-
moter, flanking active promoter, transcription at 5′ and 3′ 
ends of a gene, strong transcription, weak transcription, 
active intragenic enhancers, active intergenic enhancers 
and poised enhancers. Three states were associated with 
bivalent chromatin: bivalent promoter, flanking bivalent 
promoter and bivalent enhancers. There were four states 
associated with ‘repressive’ chromatin: zinc finger genes 
and repeats, heterochromatin, strong polycomb and 
weak polycomb. The 15th state was ‘unmarked’ chroma-
tin that did not contain any of the histone modifications 
in the core data set. This model was applied to histone 
modification ChIP-seq data from LNCaP cells using the 
chromHMM program (v1.10) [35], and the chromatin 
states were collapsed into ‘active’, ‘repressed’, ‘bivalent’ 
and ‘unmarked’.
Chromatin remodeller enrichment and correlation analyses
To determine whether chromatin remodeller binding 
sites were enriched at the site of a specific chromatin 
factor or chromatin regulatory element (histone modi-
fications, CTCF sites, LADs, DNaseI sites, chromatin 
loop anchors, TADs, TAD boundaries, methylated and 
unmethylated CpG islands and chromHMM states), 
we used the genome association tester (GAT; v1.0) [36]. 
The observed-over-expected fold change and statistical 
significance were calculated with 10,000 iterations and 
determine significant if the p value was less than 0.05 or 
0.001. The difference between the means of the observed/
expected enrichment scores from Group 1 and Group 2 
remodellers was compared using the unpaired Student’s 
T-test in R.
We defined the percentage of overlap between each 
of the remodellers, and the remodellers with TADs and 
TAD boundaries by intersecting the peaks identified 
from the ChIP-seq and Hi-C data. Histone modification 
average signal plots over chromatin remodeller peaks and 
the heatmaps of putative active enhancers and chromatin 
remodeller signal over CpG islands and promoters were 
created with SeqPlots [89] and deepTools2 [90]. Histone 
marks were plotted ± 2 kb from the centre of the remod-
eller binding sites. At CpG islands remodeller ChIP-seq 
signal for both average plots and heatmaps were plot-
ted ± 2 kb from the centre of the island. Each row of the 
heatmap is an individual CpG island and displays the 
remodeller ChIP-seq signal, sorted by the average signal 
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across all remodellers in decreasing order. Pearson’s cor-
relation matrixes of remodellers at promoters and DNa-
seI sites were calculated in R.
Gene ontology enrichment
Gene promoters were defined as 2  kb surrounding the 
TSS of expressed genes. Read counts of the chromatin 
remodeller ChIP-seq data within the promoters regions 
of expressed genes were calculated and all Group 1 
remodellers merged and separately Group 2 remodel-
lers merged. Subtracting the total read counts of Group 
2 remodellers from Group 1 was used to define which 
promoters had a higher signal for Group 1 and which had 
a higher signal for Group 2. The promoters assigned to 
each group were analysed for enrichment of gene ontol-
ogy terms using GREAT [52], using the whole genome as 
background and assigned to the single nearest gene. GO 
terms reported are the top 10 most significant from the 
Molecular Function, Biological Process or Cellular Com-
ponent gene set, with at least 25 observed genes in the 
data set.
Additional file
Additional file 1: Figure S1. A) Gene expression of each remodeller 
protein in LNCaP cells from RNA‑seq (mean and SE; n = 3). B) Gene expres‑
sion of remodeller proteins in TCGA data set of 486 prostate epithelial 
tumours (mean and SE; n = 486). C) Gene expression of each remodeller 
in PrEC cells from RNA‑seq (mean and SE; n = 3), D) Gene expression of 
remodellers in TCGA data set of normal prostate epithelial tissue (mean 
and SE; n = 52). E) Scatter plot of logRPKM values for TCGA data versus 
logTPM values for LNCaP and PrEC RNA‑seq data. The PrEC comparison 
for PrEC and normal TCGA is shown in green, and the LNCaP compared 
to TCGA tumours is shown in red. Lines are linear regression line of best 
fit, and Pearson’s correlation coefficient between the two normal data 
sets (cor = 0.670013) and the two cancer data sets (cor = 0.8375552, 
SNF2L is excluded as an outlier) is shown under the plot. Figure S2. A–H) 
Histograms of chromatin remodeller binding sites, binned at 150 bp 
widths. Vertical line indicates the point of 750 bp (~ 5 nucleosomes). 
Figure S3. A) Heat map of ChromHMM emission profile based on the 
learned model from the epigenome roadmap. B) Heat map of chromatin 
state enrichment generated from the chromHMM analysis, where the 
percentage of each state in the genome is represented in the first column 
and the remaining columns are the enrichment of each chromatin state 
over annotated genomic features. C) Heatmap of H3K27ac, H3K4me1, 
H3K4me3 and p300 ChIP‑seq signal and DNaseI signal at putative active 
enhancers, ± 2.5 kb from the centre of each enhancer, sorted by H3K27ac 
and H3K4me1 signal. Figure S4. A) Heatmap H3K4me3, RNA polII, and 
chromatin remodeller ChIP‑seq signal and DNaseI signal at refseq‑
annotated promoters. Signal is plotted ± 2 kb from the transcription start 
site (TSS) and sorted by H3K4me3 signal. B, D) Venn diagram of chromatin 
remodeller binding site overlaps for Group 1 and Group 2 remodellers, 
respectively. C) Percentage of all Group 1 remodeller binding sites that 
are unique to each Group 1 remodeller and contain multiple Group 1 
remodellers. E) Percentage of all Group 2 remodeller binding sites that are 
unique to each Group 2 remodeller and contain multiple Group 2 remod‑
ellers. Figure S5. A–O) Enrichment of chromatin remodeller binding sites 
across the 15 state chromHMM model based on the Epigenome roadmap 
(see Methods). Significant enrichment is defined as a score above one and 
significantly depleted as below one with Benjamini–Hochberg adj p‑value, 
***p < 0.001 or **p < 0.05. Figure S6. A–D) Genome‑wide average distribu‑
tion of ChIP‑seq signals for histone modifications H3K4me3, H3K4me1, 
H3K27me3 and H3K9me3 ± 2 kb from the centre of chromatin remodel‑
ler binding sites. E–H) Pearson’s correlation score matrix of chromatin 
remodeller ChIP‑seq signal at active, bivalent, facultative and constitutive 
promoters. Each matrix was ordered by hierarchical clustering. Figure S7. 
A–B) Violin plots of nucleotide frequency within remodeller binding sites 
for Group 1 and Group 2. C–D) Dinucleotide frequency within chromatin 
remodeller Group 1 and Group 2 binding sites. E) DNA methylation den‑
sity within chromatin remodeller binding sites for each remodeller. F) CpG 
density within chromatin remodellers binding sites for each remodeller 
protein. G) CpG density of unmethylated CpG islands, methylated CpG 
islands and the whole genome. A significant difference in CpG density 
was detected between each of the groups (one‑way ANOVA, ***p < 0.001). 
Figure S8. A) The genome divided into TADs (85.4%), TAD boundaries 
(2.6%) and unorganised chromatin (12.0%) using TADs and boundaries 
called to a 40 kb resolution from Hi‑C data. B–C) GAT enrichment of chro‑
matin remodellers at TADs and TAD boundaries, where significant enrich‑
ment is defined as a score above one and significantly depleted as below 
one with Benjamini–Hochberg adj p‑value, ***p < 0.001 or **p < 0.05.
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